RNAZ White background cropped.jpg
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
29 mai 2024 09h15 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
RNAZ White background cropped.jpg
TransCode Therapeutics Open Letter to Shareholders
13 mai 2024 08h30 HE | TransCode Therapeutics, Inc.
An Open Letter to Shareholders regarding a Reverse Stock Split
RNAZ White background cropped.jpg
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
15 avr. 2024 09h00 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
RNAZ White background cropped.jpg
TransCode Therapeutics Reports 2023 Results; Provides Business Update
03 avr. 2024 09h10 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Reports 2023 Results; Provides Business Update
RNAZ White background cropped.jpg
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
28 mars 2024 08h30 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
RNAZ White background cropped.jpg
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
11 mars 2024 09h00 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
RNAZ White background cropped.jpg
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
06 mars 2024 16h15 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
RNAZ White background cropped.jpg
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
20 févr. 2024 08h00 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
RNAZ White background cropped.jpg
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
31 janv. 2024 16h05 HE | TransCode Therapeutics, Inc.
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement, Continued Listing on the Nasdaq Stock Market
RNAZ White background cropped.jpg
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
29 janv. 2024 08h30 HE | TransCode Therapeutics, Inc.
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer